NASDAQ$FLGT
Fulgent Genetics Inc. · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Fulgent Genetics reported financial results for the first quarter of 2024.
Fulgent Genetics reported a total revenue of $64.5 million and a GAAP loss of $13.5 million, or $0.45 per share, for the first quarter of 2024. Core revenue grew 1% year-over-year to $63.2 million. The company reiterates full year 2024 core revenue guidance of $280 million.
- Total revenue was $64.5 million.
- Core revenue grew 1% year-over-year to $63.2 million.
- GAAP loss was $13.5 million, or $0.45 per share.
- Non-GAAP loss was $269,000, or $0.01 per share.
Headline financials
Revenue & EPS history
Fulgent · Revenue · Quarterly
$64.5M
Revenue by segment
Fulgent · $66M total across 1 segment · Q3 2023
- Core Revenue$66M+17.9%100.0%
Forward guidance
For the full year 2024, Fulgent continues to expect Core Revenue of approximately $280 million, GAAP loss of approximately $2.25 per share, Non-GAAP loss of approximately $1.05 per share, and Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024.
Tailwinds
- Core Revenue of approximately $280 million
- Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024
- Remain on track with operational objectives
- Strong financial position in 2024, with ample cash to execute
- Momentum in Precision Diagnostics
Headwinds
- GAAP loss of approximately $2.25 per share
- Non-GAAP loss of approximately $1.05 per share
- Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program or other expenditures outside the ordinary course of business.
- Market potential for, and the rate and degree of market adoption of, the Company’s tests
- Volatility in the Company’s results, which can fluctuate significantly from period to period
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-2.5%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.3%
Avg return
30 days after
37%
15 / 41 earnings
Positive
+38.3%
Q3 2019
Best reaction
-38.1%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.0% | -1.8% | +19.2% | |
| Q4 2025 | -38.1% | -43.5% | -37.0% | |
| Q3 2025 | +18.3% | +30.3% | +24.6% | |
| Q1 2025 | +18.7% | +8.1% | +20.1% | |
| Q4 2024 | -1.5% | +6.1% | +8.7% | |
| Q3 2024 | -9.0% | -16.3% | -8.8% | |
| Q2 2024 | +0.4% | -0.3% | -4.3% | |
| Q1 2024 | +1.2% | +0.1% | -2.8% | |
| Q4 2023 | -11.5% | -6.8% | -14.8% | |
| Q3 2023 | +14.0% | +11.1% | +15.5% | |
| Q2 2023 | -15.4% | -18.1% | -18.6% | |
| Q1 2023 | +16.1% | +23.4% | +41.4% | |
| Q4 2022 | -2.5% | +3.3% | -9.1% | |
| Q3 2022 | -8.6% | +3.3% | -2.4% | |
| Q2 2022 | -4.9% | -20.4% | -33.9% | |
| Q1 2022 | +4.4% | -4.1% | -1.6% | |
| Q4 2021 | -1.3% | +0.1% | -2.1% | |
| Q3 2021 | -1.1% | +10.5% | +4.3% | |
| Q2 2021 | -8.0% | -10.9% | -15.2% | |
| Q1 2021 | +3.9% | -2.5% | +2.6% | |
| Q4 2020 | -0.5% | +18.1% | +8.3% | |
| Q3 2020 | -17.0% | +6.9% | +20.0% | |
| Q2 2020 | +27.2% | +26.1% | +13.2% | |
| Q1 2020 | -21.0% | +3.9% | +10.3% | |
| Q4 2019 | -32.3% | -42.6% | -29.1% | |
| Q3 2019 | +38.3% | +68.1% | +26.0% | |
| Q2 2019 | +31.9% | +45.4% | +46.7% | |
| Q1 2019 | -15.8% | -16.5% | -11.3% | |
| Q4 2018 | +9.6% | +7.6% | +29.3% | |
| Q3 2018 | +6.9% | +12.3% | +2.8% | |
| Q2 2018 | -0.8% | -4.9% | -17.9% | |
| Q1 2018 | -0.3% | -2.3% | -4.9% | |
| Q4 2017 | -9.1% | -20.9% | -15.6% | |
| Q3 2017 | +0.4% | -4.0% | +0.9% | |
| Q2 2017 | -15.6% | -9.9% | -16.4% | |
| Q1 2016 | -31.1% | -30.0% | -53.4% | |
| Q1 2017 | -33.1% | -29.4% | -53.9% | |
| Q2 2016 | -3.8% | -9.0% | -7.5% | |
| Q4 2016 | +1.1% | -4.2% | -2.9% | |
| Q4 2015 | -1.6% | -1.7% | +8.2% | |
| Q3 2016 | -3.1% | -4.1% | +9.5% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro